Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE versus SODIUM CHLORIDE 0 9 AND POTASSIUM CHLORIDE 0 15 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE versus SODIUM CHLORIDE 0 9 AND POTASSIUM CHLORIDE 0 15 IN PLASTIC CONTAINER.
MAGNESIUM SULFATE vs SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate acts as a physiological calcium channel blocker. It inhibits calcium influx into presynaptic nerve terminals, reducing acetylcholine release at the neuromuscular junction and decreasing muscle contraction. It also antagonizes NMDA receptors and stabilizes neuronal membranes.
Sodium chloride (0.9%) provides isotonic sodium and chloride ions, expanding extracellular fluid volume via osmotic retention of water. Potassium chloride (0.15%) supplies potassium ions necessary for transmembrane electrochemical gradients, maintenance of cellular membrane potential, and neuromuscular function. Combination corrects hypovolemia and hypokalemia.
IV: Loading dose 4-6 g over 20-30 minutes, followed by maintenance infusion 1-2 g/hour for seizure prophylaxis in severe preeclampsia/eclampsia. IM: 4-8 g deep IM initially, then 4 g every 4 hours as needed.
Intravenous infusion: 500-1000 mL as needed to correct fluid and electrolyte deficits; rate adjusted based on patient's clinical status, typically 1-2 L/day for maintenance. Maximum rate: 20 mEq/h potassium.
None Documented
None Documented
Clinical Note
moderateMagnesium sulfate + Gatifloxacin
"The serum concentration of Gatifloxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateMagnesium sulfate + Rosoxacin
"The serum concentration of Rosoxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateMagnesium sulfate + Levofloxacin
"The serum concentration of Levofloxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateTerminal elimination half-life approximately 4-6 hours in patients with normal renal function; prolonged to 12-24 hours or more in renal impairment, necessitating dose adjustment
Not applicable as a pharmacokinetic parameter for electrolyte solutions; the elimination half-life of infused sodium, chloride, and potassium is approximately 2-4 hours, reflecting renal clearance and distribution kinetics. In clinical context, steady-state electrolyte concentrations are achieved within 1-2 hours of continuous infusion.
Primarily renal (90-95% as unchanged drug); minor biliary/fecal (<5%)
Sodium and chloride are primarily excreted renally: >90% of filtered sodium and chloride are reabsorbed in the kidneys; excess is excreted in urine. Potassium is mainly excreted renally (approximately 90%), with minor fecal (10%) and negligible biliary elimination.
Category C
Category A/B
Electrolyte
Electrolyte
Magnesium sulfate + Trovafloxacin
"The serum concentration of Trovafloxacin can be decreased when it is combined with Magnesium sulfate."